Clearmind Medicine (CMND) has submitted its tenth patent application under the international Patent Cooperation Treaty as part of its ongoing collaboration with SciSparc (SPRC). The patent applications refer to the novel proprietary composition of Clearmind’s MEAI compound with Palmitoylethanolamide, the active ingredient of SciSparc’s proprietary CannAmide, for preventing and/or treating depression. This application was previously filed as provisional patent application with the United States Patent and Trademark Office.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Here’s What You Missed in Cannabis, Psychedelics This Week
- Breakthrough in Wellness: Clearmind Medicine’s Psychedelic Treatment Granted Divisional Patent Approval in China
- Clearmind Medicine granted divisional patent approval in China
- Rising High: Exclusive talk with cannabis market research firm BDSA
- Clearmind Medicine Streamlines NASDAQ Trading